Recombinant Human PLA2G7/Lp-PLA2 Protein (His Tag)(Active)
Size: 50μg
Catalogue Number: PKSH031390-50
Citations, Manuals and MSDS Available upon request.
Abbreviation: PLA2G7; Lp-PLA2
Target Symptom: 2-acetyl-1-alkylglycerophosphocholine esterase; EC 3.1.1; EC 3.1.1.47; 1-alkyl-2-acetylglycerophosphocholine esterase; Group-VIIA phospholipase A2; gVIIA-PLA2; LDL-associated phospholipase A2; LDL-PLA(2); LDL-PLA2; lipoprotein-associated phospholipase A2; LpPLA2; Lp-PLA2; PAF acetylhydrolase; PAF-AH; PAFAHPAF 2-acylhydrolase; phospholipase A2; group VII (platelet-activating factor acetylhydrolase; PLA2G7; plasma); platelet-activating factor acetylhydrolase
Target Species: Human
Expression Host: HEK293 Cells
Application: Enzyme
Fusion Tag: C-His
UNIProt ID: Q13093
Accession: Q13093-1
Background: Platelet-activating factor acetylhydrolase; also known as 1-alkyl-2-acetylglycerophosphocholine esterase; 2-acetyl-1-alkylglycero-phosphocholine esterase; Group-VIIA phospholipase A2; LDL-associated phospholipase A2; PAF 2-acylhydrolase; PLA2G7 and PAFAH; is secreted protein which belongs to theAB hydrolase superfamily and Lipase family. PLA2G7 / PAFAH modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. It has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. PLA2G7 / PAFAH is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes; including cardiovascular disease. PLA2G7 also represents an important; potentially functional candidate in the pathophysiology of coronary artery disease (CAD). Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PLA2G7 deficiency). It is a trait which is present in 27% of Japanese. It could have a significant physiologic effect in the presence of inflammatory bodily responses.
Activity: Measured by its ability to cleave a colorimetric peptide substrate, 1O-hexadecyl-2-deoxy-2-thio Sacetylsnglyceryl-3-phosphoryl choline (2-Thio-PAF), in the presence of 5, 5’Dithiobis(2-nitrobenzoic acid) (DTNB). The specific activity is > 5000 pmoles/min/μg.
Sequence: Met 1-Asn 441
Purity: > 88 % as determined by reducing SDS-PAGE.
Formulation: Lyophilized from sterile 50mM NaAc, 150mM NaCl, 10% glycerol, pH 5.0
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Reconstitution: Please refer to the printed manual for detailed information.
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
Calculated MW: 49.2 kDa
Observed MW: 50-55 kDa
Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Research Use Only